CD46 and neoplasm: This phenomenon could be due to the expression of several different complement-regulatory proteins (CRPs) by tumor cells, such as CD46, CD55, and CD59, which inhibit complement activation and confer resistance of tumor cells to killing mediated by CDC [42].